Sergei Petukhov

Founder

2017

Founder

2025

Chief Business Officer

2025

At Khepri, we're revolutionizing the landscape of pet care with a singular focus on improving the lives of aging companions. With Khepri, we're not just adding years to pets' lives; we're adding life to their years, redefining what it means to age gracefully in the animal kingdom. Our groundbreaking approach leverages advanced metabolic gene therapies to target the root cause of age-related decline—systemic inflammation—treating life-threatening conditions and dramatically improving pet’s overall quality of life.

Founder

2025

As the largest Central Asian biobank, we help companies understand complex biology by providing access to patients around the world, high-quality biospecimens, and machine learning-ready datasets. We support both preclinical and clinical research, with a focus on underrepresented geographic regions and diverse patient populations.

Chief Executive Officer

2024

Metallomix emerged to revolutionize medicine with our distinctive scientific perspective on disease pathogenesis. Our approach is rooted in over ten years of research that delves deeper than molecular patterns, exploring the isotopic signatures at the atomic level within cells and tissues as part of metalloproteomics.Metallomix emerged to revolutionize medicine with our distinctive scientific perspective on disease pathogenesis. Our approach is rooted in over ten years of research that delves deeper than molecular patterns, exploring the isotopic signatures at the atomic level within cells and tissues as part of metalloproteomics.

Managing Director

2021 - 2024

The AMR Action Fund aims to bring 2-4 new antibiotics to patients by 2030. We will work with partners to create market conditions that enable sustainable investment in the antibiotic pipeline. The AMR Action Fund expects to invest more than US$1 billion in smaller biotech companies and provide industry expertise to support the clinical development of novel antibiotics.

Board Member

2022 - 2023

World leader in antibacterial & antiviral drug research and development. Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.

Venture Partner

2019 - 2021

Starta Ventures is a seed stage fund with a focus on startups with European R&D roots. Role: Advisory / mentorship Duties: - Advising health-tech companies on development strategies - Providing guidance on clinical path and market fit - Assisting with the accelerator’s capital raise activities - Reporting to LPs, writing the accelerator’s health-tech strategic developmental plan

President

2017 - 2021

Kadem LLC is an advisory firm that provides consultancy services to its clients within biotech and cleantech fields

Vice President Of Business Development

2020 - 2021

Monet Pharmaceuticals has created a novel structural biology Protein Painting Platform (PPP) designed to identify new druggable hot spots in protein-protein (P2P) interactions. PPP is versatile and can be applied to facilitate the discovery of novel biologic therapeutics across a diverse range of disease areas, including oncology, autoimmune and rare diseases. Fundamentally, PPP provides a unique insight into the interactions between protein complexes that fundamentally differs from was previously allowed by the other methods.